Cargando…

Newcastle Disease Virus/HK84: Next Potential Star for Targeted Immunotherapy of Hepatocellular Carcinoma?

Detalles Bibliográficos
Autores principales:	Huang, Weiyi, Chang, Wenjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Inc. 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039706/ https://www.ncbi.nlm.nih.gov/pubmed/35528986 http://dx.doi.org/10.14218/JCTH.2021.00553

Ejemplares similares

Therapeutic Use of Viruses: Newcastle Disease Virus HK84 Oncolytic Treatment for Hepatocellular Carcinoma
por: Baiocchi, Leonardo, et al.
Publicado: (2022)

Oncolytic Activity of Wild-type Newcastle Disease Virus HK84 Against Hepatocellular Carcinoma Associated with Activation of Type I Interferon Signaling
por: Chen, Liming, et al.
Publicado: (2022)

Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma
por: Meng, Gang, et al.
Publicado: (2019)

Newcastle Disease Virus at the Forefront of Cancer Immunotherapy
por: Burman, Bharat, et al.
Publicado: (2020)

Nasopharyngeal carcinoma treatment paradigm after HK0501 – a potential way forward
por: Poh, Sharon S, et al.
Publicado: (2022)

Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus
por: Meng, Qiuxing, et al.
Publicado: (2021)

miR-202 functions as a tumor suppressor in hepatocellular carcinoma by targeting HK2
por: Wang, Jiangang, et al.
Publicado: (2020)

Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Regulation of HK2 expression through alterations in CpG methylation of the HK2 promoter during progression of hepatocellular carcinoma
por: Lee, Hyun Gyu, et al.
Publicado: (2016)

Editorial JVE 8.4
Publicado: (2022)

Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma
por: Shiina, Shuichiro, et al.
Publicado: (2023)

Fludarabine as an Adjuvant Improves Newcastle Disease Virus-Mediated Antitumor Immunity in Hepatocellular Carcinoma
por: Meng, Gang, et al.
Publicado: (2019)

The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Hypoxia features as potential indicators in prognosis, immunotherapy and drug screening in hepatocellular carcinoma patients
por: Gao, Ruize
Publicado: (2022)

Overcoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells
por: Qin, Guohui, et al.
Publicado: (2023)

Targets of immunotherapy for hepatocellular carcinoma: An update
por: Rai, Vikrant, et al.
Publicado: (2022)

T and NK Cell-Based Immunotherapy in Chronic Viral Hepatitis and Hepatocellular Carcinoma
por: Fisicaro, Paola, et al.
Publicado: (2022)

Immunotherapy for the treatment of hepatocellular carcinoma: finally in clinical practice
por: Celsa, Ciro, et al.
Publicado: (2023)

Immunotherapy failure in adrenocortical cancer: where next?
por: Cosentini, Deborah, et al.
Publicado: (2018)

Next generation of cancer immunotherapy calls for combination
por: Cappello, Paola, et al.
Publicado: (2017)

Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
por: Schirrmacher, Volker, et al.
Publicado: (2022)

Glioma immunoediting, a driver of tumor evolution, and the next battle for immunotherapy
por: Sonabend, Adam M., et al.
Publicado: (2021)

Transcriptome Analysis of Natural Killer Cells in Response to Newcastle Disease Virus Infected Hepatocellular Carcinoma Cells
por: Huang, Juanjuan, et al.
Publicado: (2023)

Identification of Newcastle disease virus P-gene editing using next-generation sequencing
por: CHEN, Xi, et al.
Publicado: (2020)

Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma
por: Yoo, So Young, et al.
Publicado: (2017)

Phosphorylation of PPARγ at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4
por: Shu, Yuxin, et al.
Publicado: (2016)

The next age of immunotherapy: optimisation, stratification and therapeutic synergies
por: Halama, Niels
Publicado: (2018)

CSBB: synthetic biology research at Newcastle University
por: Goñi-Moreno, Angel, et al.
Publicado: (2017)

Targeting Angiogenesis for Advanced Hepatocellular Carcinoma
por: Eso, Yuji
Publicado: (2020)

Hepatitis B and C Viruses and Hepatocellular Carcinoma
por: Bartosch, Birke
Publicado: (2010)

Next Generation Sequencing‐Based Identification of T‐Cell Receptors for Immunotherapy Against Hepatocellular Carcinoma
por: Ma, Yipeng, et al.
Publicado: (2021)

Lipids link immune suppression to effective immunotherapy in steatotic hepatocellular carcinoma
por: Li, Bing, et al.
Publicado: (2023)

HK1 from hepatic stellate cell–derived extracellular vesicles promotes progression of hepatocellular carcinoma
por: Chen, Qi-tao, et al.
Publicado: (2022)

Newcastle Disease Virus Hemagglutinin Neuraminidase as a Potential Cancer Targeting Agent
por: Baradaran, Ali, et al.
Publicado: (2016)

Rising Star
por: Wojtys, Edward M.
Publicado: (2012)

Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
por: Harper, James, et al.
Publicado: (2021)

Report of the Central Veterinary School at Munich, Bavaria, for the Years 1883–84
Publicado: (1885)

Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
por: Contratto, Merly, et al.
Publicado: (2018)

Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma
por: Dai, Xiaomeng, et al.
Publicado: (2021)

Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma
por: Laface, Carmelo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_87soa4k8684lili1200hm9ohkm